sinulariolide: isolated from the marine mollusk Planaxis sulcatus; RN not in Chemline 12/86 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5358848 |
MeSH ID | M0143591 |
Synonym |
---|
episinulariolide |
nsc306684 |
nsc-306684 |
sinulariolide |
56326-25-1 |
4,5]octadec-8-en-15-one, 12-hydroxy-5,9,13-trimethyl-16-methylene-, [1r-(1r*,3s*,5s*,8e,12s*,13r*)]- |
nsc-285705 |
(8e)-12-hydroxy-5,9,13-trimethyl-16-methylidene-4,14-dioxatricyclo[11.3.2.03,5]octadec-8-en-15-one |
Sinulariolide is an active compound isolated from the cultured soft coral Sinularia flexibilis.
Sinulariolide treatment led to loss of the mitochondrial membrane potential, release of mitochondrial cytochrome c to the cytosol, and activation of both caspase-9 and caspases-3. Food treated with sinulariolides was generally accepted at a 1% concentration.
Excerpt | Reference | Relevance |
---|---|---|
"Sinulariolide treatment led to loss of the mitochondrial membrane potential, release of mitochondrial cytochrome c to the cytosol, and activation of both caspase-9 and caspase-3." | ( Sinulariolide induced hepatocellular carcinoma apoptosis through activation of mitochondrial-related apoptotic and PERK/eIF2α/ATF4/CHOP pathway. Chao, HH; Chen, YJ; Huang, HH; Hung, CT; Liao, MH; Lin, JJ; Su, JH; Tsai, FJ; Tsao, CY; Weng, SH; Wu, YJ; Yang, ZY, 2013) | 2.55 |
"Food treated with sinulariolide (a compound previously determined to be non-bioactive) was generally accepted at a 1% concentration." | ( Discrimination between several diterpenoid compounds in feeding by Gambusia affinis. Aceret, TL; Coll, JC; Sammarco, PW; Uchio, Y, 2001) | 0.63 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (11.76) | 18.2507 |
2000's | 1 (5.88) | 29.6817 |
2010's | 12 (70.59) | 24.3611 |
2020's | 2 (11.76) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.89) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |